PDCD1LG2 and neoplasm: This may be explained by the increased expression of the PD-1 receptor and its ligands (PD-L1 and PD-L2) and high tumor mutational burden in the dMMR-MSI-H subtype, making them potentially sensitive to treatment with PD-1 inhibitors and PD-L1 inhibitors.